A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT ID: NCT04734197

Last Updated: 2025-05-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 349 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-11
• Study Completion Date: 2022-03-25

Brief Summary

SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.

The purpose of this research study is to see how well SURF-100 works to treat dry eye and what potential side effects there are, and to compare it with Vehicle (placebo), 0.1% mycophenolic acid (MPA) in Vehicle, 0.3% MPA in Vehicle, 0.01% betamethasone phosphate (BSP) in Vehicle, Restasis and Xiidra. This study will involve about 280-350 study participants age 18 and older at about 40 different research sites in the United States.

Conditions

Dry Eye Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SURF-100 (a combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days

Group Type: EXPERIMENTAL

SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)

Intervention Type: DRUG

combination of a topical immunosuppressant and a topical corticosteroid solution

Mycophenolic Acid 0.1%

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.

Group Type: EXPERIMENTAL

Mycophenolic Acid 0.1%

Intervention Type: DRUG

topical immunosuppressant

Mycophenolic Acid 0.3%

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.

Group Type: EXPERIMENTAL

Mycophenolic Acid 0.3%

Intervention Type: DRUG

topical immunosuppressant

Betamethasone Sodium Phosphate 0.01%

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.

Group Type: EXPERIMENTAL

Betamethasone Sodium Phosphate 0.01%

Intervention Type: DRUG

topical corticosteroid solution

Vehicle

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days.

Group Type: PLACEBO_COMPARATOR

Placebo Comparator: Vehicle

Intervention Type: DRUG

topical vehicle solution

Cyclosporine 0.05% Ophthalmic Emulsion

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days

Group Type: ACTIVE_COMPARATOR

Cyclosporine 0.05% Ophthalmic Emulsion

Intervention Type: DRUG

topical ophthalmic emulsion

Lifitegrast 5% Ophthalmic Solution

One drop in the study eye (and fellow eye, if applicable) twice daily for 84 days

Group Type: ACTIVE_COMPARATOR

Lifitegrast 5% Ophthalmic Solution

Intervention Type: DRUG

topical ophthalmic solution

Interventions

SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)

combination of a topical immunosuppressant and a topical corticosteroid solution

Intervention Type: DRUG

Mycophenolic Acid 0.1%

topical immunosuppressant

Intervention Type: DRUG

Mycophenolic Acid 0.3%

topical immunosuppressant

Intervention Type: DRUG

Betamethasone Sodium Phosphate 0.01%

topical corticosteroid solution

Intervention Type: DRUG

Placebo Comparator: Vehicle

topical vehicle solution

Intervention Type: DRUG

Cyclosporine 0.05% Ophthalmic Emulsion

topical ophthalmic emulsion

Intervention Type: DRUG

Lifitegrast 5% Ophthalmic Solution

topical ophthalmic solution

Intervention Type: DRUG

Other Intervention Names

Restasis 0.05% ophthalmic emulsion; Xiidra 5% Ophthalmic Solution

Eligibility Criteria

Inclusion Criteria

1. Adults at least 18 years of age at the time of the Screening visit.

2. Willing and able to read, sign, and date the informed consent form (ICF) after the nature of the study has been explained and any questions have been answered, and prior to initiation of any study procedures or exams.

3. Willing and able to comply with all study procedures and attend all study visits.

4. Willing to suspend use of tear substitutes at least 72 hours prior to Visit 2 (Day 0) through Visit 7 (Day 98).

5. Best corrected visual acuity (BCVA) of 0.7 log of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1 (Day -14 to Day 0).

6. Subject-reported history of dry eye in both eyes.

7. Meeting ALL of the following criteria in the same eye at Visit 1 (Day -14 to Day 0) and meeting ALL of the following criteria in the same eye at Visit 2 (Day 0) if Visit 2 is performed >5 days after Visit 1:

1. Minimum score of greater than or equal to 5 but less than or equal to 9 on UNC DEMS questionnaire.

2. Schirmer Tear Test (with anesthesia) equal to or less than 10 mm, but more than 1 mm.

3. TBUT: Equal to or less than 5 seconds

8. A negative urine pregnancy test if female and of childbearing potential (those who are not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral oophorectomy] or post-menopausal [12 months after last menses] or premenarchal) and must have used adequate birth control throughout the study period (through Visit 7 [Day 98]). Adequate birth control is defined as hormonal-oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device; abstinence; or surgical sterilization of male partner.

Exclusion Criteria

1. Contraindications or known hypersensitivity to the study drug(s), including RESTASIS or XIIDRA, or their components.

2. Subjects who are employees or immediate family members of employees at the investigational site.

3. Subjects who are members of the same household.

4. Any ocular condition that, in the opinion of the investigator, may affect study parameters including, but not limited to, lid margin disorders (e.g., blepharitis including staphylococcal, demodex, or seborrheic; excessive lid laxity, floppy eyelid syndrome, ectropion, entropion), advanced conjunctivochalasis, Salzmann's nodular degeneration, and asthenopia-related conditions, allergic conjunctivitis, glaucoma, diabetic retinopathy, follicular conjunctivitis, iritis, uveitis, wet-exudative age-related macular degeneration, retinal vein occlusion, and/or active ocular inflammation.

5. Any condition that could affect trigeminal nerve function including facial or ocular Herpes Zoster/Shingle, a stroke or nerve palsy affecting the eye(s).

6. Use of any topical medication and/or antibiotics for the treatment of blepharitis or meibomian gland disease in either eye within 14 days prior to Visit 2 (Day 0).

7. Active or history of ocular herpes or any other ocular infection in either eye within the last 30 days prior to Visit 1 (Day -14 to Day 0).

8. Unwilling to avoid wearing contact lenses for 7 days prior to Randomization (Visit 2, Day 0) and for the duration of the study period (through Visit 7, Day 98).

9. Positive urine pregnancy test at Screening, nursing an infant or planning to become pregnant during the study.

10. Any blood donation or significant loss of blood within 56 days of Visit 1 (Day -14 to Day 0).

11. Any history of immunodeficiency disorder, human immunodeficiency virus (HIV), positive hepatitis B, C, or evidence of acute active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone marrow transplant.

12. Any medication (oral or topical) known to cause ocular drying that is not administered as a stable dose for at least 30 days prior to Visit 1 (Day -14 to Day 0) and for the duration of the study (Visit 7, Day 98); antihistamines are not allowed at any time during the study.

13. Use of prohibited medications (topical, topical ophthalmic and/or systemic, during the appropriate pre-study washout period (see below) and during the study. Prohibited medications include topical cyclosporine or lifitegrast, use of any other ophthalmic medication (e.g., glaucoma medication, topical anti-inflammatory eye drops) for the duration of the study)

NOTE: Supplements containing omega-3 are allowed if the subject has been taking said supplement for at least 3 months prior to Screening. Subjects are not allowed to begin taking supplements containing omega-3 during the study. The appropriate pre-study washout period is as follows:

1. Antihistamines (including ocular): 7 days prior to Visit 1 (Day -14 to Day 0).

2. Topical cyclosporine or lifitegrast or omega-3s within 14 days prior to Visit 1 (Day -14 to Day 0).

3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1 (Day -14 to Day 0).

4. Depot-corticosteroids in either eye at least 45 days prior to the first dose of study drug (Day 0)

5. All other topical ophthalmic preparations (including artificial tear substitutes other than the study drops): 72 hours prior to Visit 1 (Day -14 to Day 0).

6. Introduction of any new, nonsteroidal anti-inflammatory drugs (NSAIDs) including but not limited to topical, systemic (including sleep-aids containing NSAIDs), inhaled, or irrigation solution within 7 days prior to the first dose of study drug. Subjects who are on stable dose of NSAIDs (stable for at least 4 weeks prior to the first dose of study drug) are eligible for participation and should remain on a stable dose throughout the duration of the study (i.e., through Day 98).

7. Triamcinolone in either eye at least 90 days prior to the first dose of study drug (Day 0).

8. Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) at least 7 days prior to the first dose of study drug (Day 0).

9. Systemic pain relievers, analgesics (e.g., pregabalin, gabapentin, opioids) 14 days prior to the first dose of study drug (Day 0).

10. Any supplement, prescribed medication or over-the-counter product that the investigator feels may interfere with the study parameters, including homeopathic remedies, analgesics, and pain medication.

11. Oral doxycycline within 6 months of first dose of study drug (Day 0).

12. Diuretics: Within 28 days prior to Visit 1 (Day -14 to Day -1).

13. Punctal occlusion:

i. Punctal cauterization: Randomization may not occur until 4 weeks following the procedure.

ii. Permanent/semi-permanent punctal plugs (this includes 180-day punctal plugs): Randomization may not occur until 4 weeks following the procedure. If a punctal plug falls out during the study, it should be reinserted.

iii. Temporary collagen punctal plugs: Not permitted. If subject has a history of use of temporary punctal plugs, randomization may not occur until 4 weeks since last insertion and puncta are plug-free, as determined by the investigator.

14. Any significant chronic illness that, in the opinion of the investigator, could interfere with the study parameters, including, but not limited to, severe cardiopulmonary disease, poorly controlled hypertension, and/or poorly controlled diabetes.

15. Use of any investigational product or device within 30 days prior to Visit 1 (Day -14 to Day 0) or during the study period.

16. History of LASIK or similar type of corneal refractive surgery within 12 months prior to Visit 1 (Day -14 to Day 0), and/or any other ocular surgical procedure within 12 months prior to Visit 1 (Day -14 to Day 0); or any scheduled ocular surgical procedure during the study period.

17. Use of any laser procedure for the eyes in the 30 days prior to Visit 1 (Day -14 to Day 0).

18. Known history of alcohol and/or drug abuse within the past 12 months that in the opinion of the principal investigator, may interfere with study compliance, outcome measures including safety parameters, and/or the general medical condition of the subject.

19. Subjects with dry eye secondary to scarring (such as that seen with irradiation, alkali burns, Stevens Johnson syndrome, cicatricial pemphigoid) or destruction of conjunctival goblet cells (as with vitamin A deficiency) are not eligible for the study. Subjects with incidental scars secondary to refractory surgery (i.e., LASIK surgery) that, in the opinion of the principal investigator, would not interfere with study compliance and/or outcome measures, are not excluded from the study.

20. Subjects who test positive for the COVID-19 virus within 30 days prior to Visit 1 (Day -14 to Day 0).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Surface Ophthalmics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kamran Hosseini, MD, PhD

Role: STUDY_CHAIR

Surface Ophthalmics, Inc. (formerly Surface Pharmaceutials, Inc.)

Locations

Cornea and Cataract Consultants of Arizona PC

Phoenix, Arizona, United States

Canyon City EyeCare

Azusa, California, United States

Inland Eye Specialists

Hemet, California, United States

North Valley Eye Medical Group Inc.

Mission Hills, California, United States

LoBue Laser and Eye Medical Center

Murrieta, California, United States

Eye Research Foundation

Newport Beach, California, United States

Martel Eye Medical Group

Rancho Cordova, California, United States

Sacramento Eye Consultants, A Medical Corporation

Sacramento, California, United States

The Eye Center of Northern Colorado

Fort Collins, Colorado, United States

Connecticut Eye Consultants, PC

Danbury, Connecticut, United States

Florida Eye Microsurgical Institute, Inc.

Boynton Beach, Florida, United States

Hernando Eye Institute

Brooksville, Florida, United States

Bowden Eye and Associates

Jacksonville, Florida, United States

Eye Center of North Florida PA

Panama City, Florida, United States

International Research Center

Tampa, Florida, United States

Blue Ocean Clinical Research at The Macula Center

The Villages, Florida, United States

Coastal Research Associates, LLC

Roswell, Georgia, United States

Jackson Eye

Lake Villa, Illinois, United States

Cincinnati Eye Institute

Edgewood, Kentucky, United States

Kentucky Eye Institute

Lexington, Kentucky, United States

Midwest Vision Research Foundation at Pepose Vision Institute

Chesterfield, Missouri, United States

Tauber Eye Center

Kansas City, Missouri, United States

Tekwani Vision Center

St Louis, Missouri, United States

Ophthalmology Consultants Ltd.

St Louis, Missouri, United States

EyeSight Ophthalmic Services

Somersworth, New Hampshire, United States

Alterman, Modi & Wolter

Poughkeepsie, New York, United States

Rochester Ophthalmological Group, PC

Rochester, New York, United States

Physicians Protocol

Greensboro, North Carolina, United States

Scott & Christie and Associates, PC

Cranberry Township, Pennsylvania, United States

Black Hills Regional Eye Institute

Rapid City, South Dakota, United States

Total Eye Care, PA

Memphis, Tennessee, United States

VRF Eye Specialty Group

Memphis, Tennessee, United States

West TN EyeCare dba Toyos Clinic

Nashville, Tennessee, United States

Texan Eye Care, PA - Keystone Research, Ltd

Austin, Texas, United States

Houston Eye Associates

Houston, Texas, United States

Advanced Laser Vision & Surgical Institute

Houston, Texas, United States

Eye Clinics of South Texas, PA

San Antonio, Texas, United States

R and R Eye Research, LLC

San Antonio, Texas, United States

Tanner Clinic

Layton, Utah, United States

The Eye Institute of Utah

Salt Lake City, Utah, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

C-100-001

Identifier Type: -

Identifier Source: org_study_id